This study looked at the association of cystatin-C (cys-C) with severity of metabolic syndrome in Asian Indians.
Methods:
Five sets of normal glucose tolerance subjects were recruited from the Chennai Urban Rural Epidemiology Study (CURES), a population-based study in southern India: 43 subjects with no metabolic risk factors, 44 subjects with one metabolic risk factor, 37 subjects with two risk factors, 40 subjects with three risk factors, and 40 subjects with four or five metabolic risk factors. Metabolic syndrome was defined using National Cholesterol Education Program criteria for adults modified for waist measured using the World Health Organization Asia Pacific guidelines. Serum cys-C was estimated by a high-sensitivity particle-enhancing nephelometry assay.
Results:
Subjects with four or five metabolic abnormalities had the highest cys-C levels, and with decreasing number of metabolic abnormalities, the cys-C levels decreased linearly (P for trend < 0.001). Regression analysis showed a linear increase in cys-C levels with increasing number of metabolic abnormalities.
Conclusion:
Cys-C levels are highly correlated with the number of metabolic abnormalities in Asian Indians.
Get full access to this article
View all access options for this article.
References
1.
FordES, LiC, CookS, ChoiHK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation, 2007; 115:2526–2532.
2.
HuG, LindströmJ, JousilahtiP, PeltonenM, SjöbergL, KaajaR, SundvallJ, TuomilehtoJ. The increasing prevalence of metabolic syndrome among Finnish men and women over a decade. J Clin Endocrinol Metab, 2008; 93:832–836.
3.
FordES, GilesWH, MokdadAH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 2004; 27:2444–2449.
4.
LiZY, XuGB, XiaTA. Prevalence rate of metabolic syndrome and dyslipidemia in a large professional population in Beijing. Atherosclerosis, 2006; 184:188–192.
5.
DeepaM, FarooqS, DattaM, DeepaR, MohanV. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34)Diabetes Metab Res Rev, 2007; 23:127–134.
6.
EnasEA, MohanV, DeepaM, FarooqS, PazhoorS, ChennikkaraH. The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. J Cardiometab Syndr, 2007; 2:267–275.
7.
TurkV, BodeW. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett, 1991; 22;285:213–219.
8.
SurendarJ, AnuradhaS, AshleyB, BalasubramanyamM, AravindhanV, RemaM, MohanV. Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in Asian Indian subjects with glucose intolerance (CURES-32)Metab Syndr Relat Disord, 2009; 7:419–425.
9.
ShiGP, SukhovaGK, GrubbA, DucharmeA, RhodeLH, LeeRT, RidkerPM, LibbyP, ChapmanHA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest, 1999; 104:1191–1197.
10.
SongSH, KwakIS, KimYJ, LeeHS, RheeH, LeeDW, KangYH, KimSJ. Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hypertens Res, 2008; 31:1895–1902.
11.
MaahsDM, OgdenLG, KretowskiA, Snell-BergeonJK, KinneyGL, BerlT, RewersM. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes, 2007; 56:2774–2779.
12.
ShlipakMG, KatzR, KestenbaumB, FriedLF, SiscovickD, SarnakMJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis, 2009; 204:298–303.
13.
ShlipakMG, SarnakMJ, KatzR, FriedLF, SeligerSL, NewmanAB, SiscovickDS, Stehman-BreenC. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005; 352:2049–2060.
14.
ShlipakMG, Wassel FyrCL, ChertowGM, HarrisTB, KritchevskySB, TylavskyFA, SatterfieldS, CummingsSR, NewmanAB, FriedLF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol, 2006; 17:254–261.
15.
KoenigW, TwardellaD, BrennerH, RothenbacherD. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem, 2005; 51:321–327.
16.
ShlipakMG, KatzR, FriedLF, JennyNS, Stehman-BreenCO, NewmanAB, SiscovickD, PsatyBM, SarnakMJ. Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol, 2005; 45:268–271.
17.
JernbergT, LindahlB, JamesS, LarssonA, HanssonLO, WallentinL. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation, 2004; 110:2342–2348.
18.
NiL, LüJ, HouLB, YanJT, FanQ, HuiR, CianfloneK, WangW, WangDW. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke, 2007; 38:3287–3288.
19.
RetnakaranR, ConnellyPW, HarrisSB, ZinmanB, HanleyAJ. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol, 2007; 22:1007–1013.
20.
ServaisA, GiralP, BernardM, BruckertE, DerayG, Isnard BagnisC. Is serum cystatin-C a reliable marker for metabolic syndrome?Am J Med, 2008; 121:426–432.
21.
DemircanN, GurelA, ArmutcuF, UnalacakM, AktuncE, AtmacaH. The evaluation of serum cystatin C, malondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit, 2008; 14:CR97–CR101.
22.
DeepaR, GokulakrishnanK, MohanV. Coronary artery disease among Indian diabetic subjects. Mohan V, Rao GHR, eds. Type 2 Diabetes in South Asians: Epidemiology, Risk Factors and Prevention. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2006; 242–255.
23.
DeepaM, PradeepaR, RemaM, MohanA, DeepaR, ShanthiraniS, MohanV. The Chennai Urban Rural Epidemiology Study (CURES)—study design and methodology (urban component) (CURES-I)J Assoc Physicians India, 2003; 51:863–870.
24.
RemaM, MohanV, DeepaR, RavikumarR. Association of carotid intima-media thickness, arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Chennai Urban Rural Epidemiology Study-2. Diabetes Care, 2004; 27:1962–1967.
25.
UnnikrishnanRI, RemaM, PradeepaR, DeepaM, ShanthiraniCS, DeepaR, MohanV. Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45)Diabetes Care, 2007; 30:2019–2024.
26.
VargheseA, DeepaR, RemaM, MohanV. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J, 2001; 77:399–402.
27.
Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001; 285:2486–2497.
28.
World Health Organization Western Pacific Region World Health Organization. International Association for the Study of Obesity; International Obesity Task Force: The Asia Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia Pty Ltd., 2000; 17–21.
29.
LeveyAS, BoschJP, LewisJB, GreeneT, RogersN, RothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999; 130:461–470.
30.
DonahueRP, StrangesS, RejmanK, RafalsonLB, DmochowskiJ, TrevisanM. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care, 2007; 30:1724–1729.
31.
LucG, BardJM, LesueurC, ArveilerD, EvansA, AmouyelP, FerrieresJ, Juhan-VagueI, FruchartJC, DucimetiereP. PRIME Study Group. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis, 2006; 185:375–380.
32.
WasénE, IsoahoR, MattilaK, VahlbergT, KiveläSL, IrjalaK. Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis, 2003; 42:36–43.
33.
KnightEL, VerhaveJC, SpiegelmanD, HillegeHL, de ZeeuwD, CurhanGC, de JongPE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int, 2004; 65:1416–1421.
34.
MuntnerP, WinstonJ, UribarriJ, MannD, FoxCS. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med, 2008; 121:341–348.
35.
NaourN, FellahiS, RenucciJF, PoitouC, RouaultC, BasdevantA, DutourA, AlessiMC, BastardJP, ClémentK, Guerre-MilloM. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring), 2009; 17:2121–2126.
36.
ShlipakMG, KatzR, CushmanM, SarnakMJ, Stehman-BreenC, PsatyBM, SiscovickD, TracyRP, NewmanA, FriedL. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med, 2005; 118:1416.
37.
Leung-TackJ, TaveraC, MartinezJ, ColleA. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation, 1990; 14:247–258.
38.
Leung-TackJ, TaveraC, GensacMC, MartinezJ, ColleA. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res, 1990; 188:16–22.
39.
NataliA, PucciG, BoldriniB, SchillaciG. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol, 2009; 22:29–38.
40.
JernbergT, LindahlB, JamesS, LarssonA, HanssonLO, WallentinL. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation, 2004; 110:2342–2348.
41.
PatelPC, AyersCR, MurphySA, PeshockR, KheraA, de LemosJA, BalkoJA, GuptaS, MammenPP, DraznerMH, MarkhamDW. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail, 2009; 2:98–104.
42.
GuFF, LüSZ, ChenYD, ZhouYJ, SongXT, JinZN, LiuH. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J (Engl), 2009; 122:2820–2826.
